<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876197</url>
  </required_header>
  <id_info>
    <org_study_id>CVB2019-1</org_study_id>
    <secondary_id>2014-004349-29</secondary_id>
    <nct_id>NCT03876197</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Study of Mesenchymal Stem Cells for Radiation-induced Xerostomia (MESRIX)</brief_title>
  <official_title>Follow-up Study of Safety and Efficacy in Subjects Who Participated in the Study of Intraglandular Mesenchymal Stem Cells in Patients With Radiation-induced Hyposalivation and Xerostomia (MESRIX) Phase 1/2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study for long-term follow-up (LTFU) to evaluate safety and efficacy in
      subjects who participated in the Phase 1/2 randomized placebo-controlled trial MESRIX.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a LTFU study to assess the long-term and late effects of treatment with MSCs or
      placebo given ultrasound-guided into the submandibular glands in subjects participating in
      the MESRIX trial. Study participants from the MESRIX trial will be invited for a clinical
      visit. The visit will include medical history, an ENT examination; measurements of the saliva
      production by sialometry, a Magnetic resonance imaging scan (MRI) and obtaining data on the
      patient-reported outcome with Xerostomia Questionnaire (XQ) and Visual-Analogue-Symptomatic
      scale (VAS). Subjects, who are not able or willing to attend a clinical visit, will be
      encouraged to fill out the Questionnaires online or on paper. If a study participant has
      deceased, information of the cause of death will be investigated in The Danish Register of
      Causes of Death
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 25, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Long-term follow-up of Randomized controlled trial MESRIX</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Serious Adverse Events (SAEs) and new chronic diseases</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>SAEs according to the ICH-GCP definition and new chronic diseases. For patients not attending the planned hospital visit consider searching The National Patient Register will be searched for registered SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Overall survival is defined as the time from the intraglandular dose of the investigational product (MSCs or placebo) to the date of death or the date the subject is last known to be alive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse of oropharyngeal cancer</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Number of participants with relapse will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New malignancies</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Number of subjects who have new malignancies will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Zoonotic Diseases</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Number of subjects diagnosed Zoonotic Diseases will be reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcome measures-Health-related quality of life (HRQoL</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Xerostomia Questionnaire (XQ) ( Median item scores for each of the 8 questions will be reported (score range 0-10) and the XQ summary/composite score (0-100))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saliva gland function</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Mean difference of unstimulated saliva productions between groups adjusted for baseline unstimulated saliva production Sialometry, unstimulated Whole saliva flow rate (ml/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of saliva</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>Mean difference of composition of saliva between groups adjusted for baseline unstimulated saliva production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Submandibular glands</measure>
    <time_frame>5 years from randomization</time_frame>
    <description>4. Mean difference of size of the submandibular glands between groups adjusted for baseline size of the submandibular glands</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Radiation Toxicity</condition>
  <condition>Xerostomia Due to Radiotherapy</condition>
  <condition>Dry Mouth</condition>
  <condition>Hyposalivation</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <condition>Mesenchymal Stromal Cells</condition>
  <condition>Long Term Adverse Effects</condition>
  <arm_group>
    <arm_group_label>Autologous Adipose-derived mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose-derived mesenchymal stem/stromal cells or placebo</intervention_name>
    <description>Intraglandular injections of Autologous adipose-derived mesenchymal stem/stromal cells or placebo</description>
    <arm_group_label>Autologous Adipose-derived mesenchymal stem cells</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Assessment of safety and treatment efficacy in subjects who were enrolled in the
             MESRIX Phase I/II clinical trial

          2. Subjects who were treated with either autologous mesenchymal stem cells or placebo

          3. Subjects who voluntarily decided to participate and signed the consent form after
             receiving explanations on the trial

        Exclusion Criteria:

        1. Subjects who were not enrolled in the MESRIX trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Lynggaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Lynggaard, MD</last_name>
    <phone>+45 6124 2795</phone>
    <email>clyn0015@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Buchwald, Professor</last_name>
    <phone>+4535452370</phone>
    <email>christian.von.buchwald@regionh.dk</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Charlotte Lynggaard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Xerostomia Due to Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
    <mesh_term>Long Term Adverse Effects</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

